The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

Letter to the Editor October 15, 2003

Worsening of Psychosis After Replacement of Adjunctive Valproate With Topiramate in a Schizophrenia Patient

Alex Hofer, MD ; W. Wolfgang Fleischhacker, MD ; Martina Hummer, MD

J Clin Psychiatry 2003;64(10):1267-1268

Article Abstract

Letter to the Editor

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu , Hiroyoshi Takeuchi

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet , André Gillibert , Barbara Mintzes , et al

Worsening of Psychosis After Replacement of Adjunctive Valproate With Topiramate in a Schizophrenia Patient

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

ELSEWHERE:

FOLLOW US:

Worsening of Psychosis After Replacement of Adjunctive Valproate With Topiramate in a Schizophrenia Patient

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Asenapine, Aggression, and Affinity

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles